Adicet Bio Inc (LTS:0HX7)
$ 0.8937 0.0228 (2.65%) Market Cap: 75.50 Mil Enterprise Value: -108.37 Mil PE Ratio: 0 PB Ratio: 0.36 GF Score: 31/100

Adicet Bio Inc R&D Day Transcript

Nov 10, 2022 / 02:00PM GMT
Release Date Price: $20.56 (+6.24%)
Chen Schor
Adicet Bio, Inc. - CEO, President & Director

Good morning, and thank you all for joining us today for our virtual R&D event. I'm Chen Schor, President and CEO of Adicet Bio. We're excited to spend the next hour providing you a deep dive into our pipeline programs. So let's go ahead and get started.

As a reminder, we'll be making forward-looking statements today as detailed on this slide. Please refer to the Risk Factors section of our most recent 10-K and subsequent SEC filings for more detail. This call is being recorded.

On the call today, I'll provide a quick introduction before handing it over to Dr. Blake Aftab, our Chief Scientific Officer, who will be giving you the bulk of today's presentation. Also joining us today is Dr. Marco Davila, Vice Chair of Cellular Therapies and Senior Vice President and Associate Director of Translational Medicine from the Roswell Park Comprehensive Cancer Center in Buffalo, New York, who is also a member of our Scientific Advisory Board. Throughout his career, Marco's clinical and bench research program have focused on developing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot